TY - JOUR
T1 - MirSNPs in clopidogrel metabolism genes predict cardiovascular disease risk
T2 - A case-control study and meta-analysis
AU - Sharma, Anu Radha
AU - Patagi, Sourav
AU - Uk, Abdul Razak
AU - Shetty, Ranjan
AU - Umakanth, Shashikiran
AU - Satyamoorthy, Kapaettu
AU - Rai, Padmalatha S.
N1 - Funding Information:
The study was supported by Indian Council of Medical Research (ICMR) (no. 3/1/2(16)/CVD/2018-NCD-II), Technology Information Forecasting and Assessment Council-Centre of Relevance and Excellence (TIFAC-CORE) in Pharmacogenomics, Dr. TMA Pai Endowment Chair in Pharmacogenomics, Manipal Academy of Higher Education, Manipal, DST-FIST, Government of India and K-FIST, Government of Karnataka.N
Publisher Copyright:
© 2020 Future Medicine Ltd.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Aim: The present study was conducted to decipher the inter-relationship of SNPs and miRNAs involved in pharmacogenomics of clopidogrel on predisposition to cardiovascular diseases (CVDs). Materials & methods: A case-control study was conducted on 410 cases and 386 controls to analyze the association of 13 mirSNPs on CVDs risk. Genotyping was performed by tetra-primer amplification refractory mutation system PCR and validated using Sanger DNA sequencing. miRNA expression analysis was performed using TaqMan assays. A meta-analysis was performed for PON1 rs662 with coronary artery disease. Results & conclusion: PON1 rs662, PON1 rs3917577, CYP3A5 rs15524, COL4A1 rs874204 and PTGIR rs1126510 polymorphisms showed association with CVDs. The miRNA hsa-miR-224-5p showed differential expression in the PON1 rs3917577 GG genotype. The meta-analysis showed the population-specific impact of PON1 rs662 on South Asian and Middle East populations.
AB - Aim: The present study was conducted to decipher the inter-relationship of SNPs and miRNAs involved in pharmacogenomics of clopidogrel on predisposition to cardiovascular diseases (CVDs). Materials & methods: A case-control study was conducted on 410 cases and 386 controls to analyze the association of 13 mirSNPs on CVDs risk. Genotyping was performed by tetra-primer amplification refractory mutation system PCR and validated using Sanger DNA sequencing. miRNA expression analysis was performed using TaqMan assays. A meta-analysis was performed for PON1 rs662 with coronary artery disease. Results & conclusion: PON1 rs662, PON1 rs3917577, CYP3A5 rs15524, COL4A1 rs874204 and PTGIR rs1126510 polymorphisms showed association with CVDs. The miRNA hsa-miR-224-5p showed differential expression in the PON1 rs3917577 GG genotype. The meta-analysis showed the population-specific impact of PON1 rs662 on South Asian and Middle East populations.
UR - http://www.scopus.com/inward/record.url?scp=85099824262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099824262&partnerID=8YFLogxK
U2 - 10.2217/pgs-2020-0110
DO - 10.2217/pgs-2020-0110
M3 - Article
C2 - 33356544
AN - SCOPUS:85099824262
SN - 1462-2416
VL - 22
SP - 99
EP - 113
JO - Pharmacogenomics
JF - Pharmacogenomics
IS - 2
ER -
